Eric Venker
Equibles does not estimate personal net worth.
Get an email with a short summary when Roivant Sciences Ltd. publishes a filing, an earnings call transcript or a press release.
Get ROIV alertsAbout Eric Venker
Eric Venker is recorded as COO and CEO at Roivant Sciences Ltd. (ROIV) and CEO at Immunovant, Inc. (IMVT). The newest filing on record that lists Eric Venker as CEO at Roivant Sciences Ltd. (ROIV) is dated July 29, 2026. The newest filing on record that lists Eric Venker as COO at Roivant Sciences Ltd. (ROIV) is dated July 26, 2024. Eric Venker was last confirmed as Board Member at Arbutus Biopharma Corp (ABUS) in a filing dated April 8, 2021. The proxy statement of Immunovant, Inc. reports total compensation of $20,158,767 for Eric Venker in fiscal 2026, including a base salary of $636,618. Disclosed compensation is on record for 7 fiscal years. Immunovant, Inc. is classified in the Biotechnology industry within the Healthcare sector. Roivant Sciences Ltd. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Immunovant, Inc. includes Eric Venker, M.D. (CEO and Board Member), Eric Venker, M.D., Pharm.D. (CEO), Dr. Frank M. Torti (Chairman) and 7 others.
Affiliation history
-
Current
Start not stated–present
Last confirmed July 26, 2024
-
Current
Start not stated–present
Last confirmed July 22, 2026
-
Current
Start not stated–present
Last confirmed July 29, 2026
-
Start not stated–2021-04-08
Last confirmed by a filing; no departure on record
Company network
Leadership on record at Immunovant, Inc.
- Eric Venker, M.D. CEO, Board Member
- Eric Venker, M.D., Pharm.D. CEO
- Dr. Frank M. Torti Chairman
- Renee Barnett CFO
- Tiago Girao CFO
- Melanie Gloria COO
- Jay S. Stout CTO
- W. Bradford Middlekauff General Counsel
- Andrew Fromkin Board Member
- Atul Pande, M.D. Board Member
Leadership on record at Roivant Sciences Ltd.
- Matthew Gline CEO, Board Member
- Richard Pulik CFO
- Jennifer Humes Chief Accounting Officer
- Daniel Gold Board Member
- Hiroshi Nomura Board Member
- Ilan Oren Board Member
- James C. Momtazee Board Member
- Keith Manchester Board Member
- Mayukh Sukhatme Board Member
- Meghan FitzGerald Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2026 | Immunovant, Inc. (IMVT) | Chief Executive Officer | $636,618 | $20,158,767 |
| 2025 | Roivant Sciences Ltd. (ROIV) | President and Immunovant CEO | $75,000 | $24,400,210 |
| 2024 | Roivant Sciences Ltd. (ROIV) | President and Immunovant CEO | $600,208 | $11,807,422 |
| 2023 | Roivant Sciences Ltd. (ROIV) | President and Immunovant CEO | $570,000 | $632,420 |
| 2022 | Roivant Sciences Ltd. (ROIV) | President and Immunovant CEO | $569,806 | $48,487,966 |
| 2021 | Roivant Sciences Ltd. (ROIV) | M.D., Pharm.D. President and Chief Operating Officer | $620,000 | $24,308,300 |
| 2020 | Roivant Sciences Ltd. (ROIV) | M.D., Pharm.D. President and Chief Operating Officer | $275,000 | $10,296,550 |
Recent activity
No call appearances or filed executive changes recorded yet.